Jane F. Apperley

51.8k total citations · 4 hit papers
442 papers, 23.7k citations indexed

About

Jane F. Apperley is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, Jane F. Apperley has authored 442 papers receiving a total of 23.7k indexed citations (citations by other indexed papers that have themselves been cited), including 376 papers in Hematology, 208 papers in Genetics and 103 papers in Rheumatology. Recurrent topics in Jane F. Apperley's work include Chronic Myeloid Leukemia Treatments (260 papers), Chronic Lymphocytic Leukemia Research (184 papers) and Hematopoietic Stem Cell Transplantation (119 papers). Jane F. Apperley is often cited by papers focused on Chronic Myeloid Leukemia Treatments (260 papers), Chronic Lymphocytic Leukemia Research (184 papers) and Hematopoietic Stem Cell Transplantation (119 papers). Jane F. Apperley collaborates with scholars based in United Kingdom, United States and Germany. Jane F. Apperley's co-authors include John M. Goldman, Richard Szydlo, Dragana Milojković, Eduardo Olavarría, Dietger Niederwieser, David Marín, Aloïs Gratwohl, Francesco Dazzi, Alistair Reid and Marco Bua and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Jane F. Apperley

436 papers receiving 23.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

1998 1.2k citations Jane F. Apperley et al. British Journal of Haematology profile →
Defining the Intensity of Conditioning Regimens: Working Definitions

2009 1.1k citations Jane F. Apperley, Shimon Slavin et al. profile →
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

2009 890 citations Jörge E. Cortes, Dietger Niederwieser et al. Journal of Clinical Oncology profile →
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

2010 674 citations David Marín, Alexandra Bazeos et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jane F. Apperley

Since Specialization

Citations

This map shows the geographic impact of Jane F. Apperley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane F. Apperley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane F. Apperley more than expected).

Fields of papers citing papers by Jane F. Apperley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane F. Apperley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane F. Apperley. The network helps show where Jane F. Apperley may publish in the future.

Co-authorship network of co-authors of Jane F. Apperley

This figure shows the co-authorship network connecting the top 25 collaborators of Jane F. Apperley. A scholar is included among the top collaborators of Jane F. Apperley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane F. Apperley. Jane F. Apperley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Positioning Imatinib for Pulmonary Arterial Hypertension: A Dose-Finding Phase 2 Study 2025 ·American Journal of Respiratory and Critical Care Medicine ·Alexander Rothman, Sofía S. Villar, Jennifer Middleton, Andreas–Antonios Roussakis, (unknown), (unknown), Martin Law, Jane F. Apperley, Imke H. Bartelink, (unknown), (unknown), David G. Kiely, Luke Howard, Mark Toshner, Stephen J. Wort, Martin R. Wilkins	6
2	Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy 2024 ·British Journal of Haematology ·H Robertson, Dragana Milojković, Nauman M. Butt, Jenny Byrne, Simone Claudiani, Mhairi Copland, Paolo Gallipoli, Andrew J. Innes, (unknown), (unknown), Jonathan Parker, (unknown), Jane F. Apperley	6
3	European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia 2023 ·Leukemia ·Nicholas C.P. Cross, Thomas Ernst, Susan Branford, Jean‐Michel Cayuela, Michael W. Deininger, Alice Fabarius, Dennis Dong Hwan Kim, Kateřina Machová Poláková, Jerald P. Radich, Rüdiger Hehlmann, Andreas Hochhaus, Jane F. Apperley, Simona Soverini	37
4	Platelet function in patients with chronic myeloid leukemia treated with asciminib 2020 ·Leukemia & lymphoma ·(unknown), Michael Laffan, Simone Claudiani, Andrew J. Innes, Jane F. Apperley, Dragana Milojković	1
5	Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working Party 2020 ·Bone Marrow Transplantation ·Éolia Brissot, Myriam Labopin, Domenico Russo, Sonja Martin, Christoph Schmid, Bertram Glaß, Ron Ram, Zübeyde Nur Özkurt, Jakob Passweg, Hendrik Veelken, Donald Bunjes, Jane F. Apperley, Sebastian Giebel, Mohamad Mohty, Arnon Nagler	15
6	TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia 2020 ·British Journal of Haematology ·Simone Claudiani, Jane F. Apperley, Richard Szydlo, Afzal Khan, (unknown), (unknown), Andrew J. Innes, Kathy Dominy, Pierre Foskett, Letizia Foroni, Jamshid S. Khorashad, Dragana Milojković	23
7	T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report 2019 ·Journal of Clinical Pathology ·Brian Hanley, (unknown), (unknown), (unknown), (unknown), (unknown), Simone Claudiani, Dragana Milojković, Edward Kanfer, Jane F. Apperley, Kikkeri N. Naresh	0
8	Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia 2019 ·Leukemia ·Susan Branford, Dennis Dong Hwan Kim, Jane F. Apperley, Christopher A. Eide, Satu Mustjoki, S. Tiong Ong, Georgios Nteliopoulos, Thomas Ernst, Charles Chuah, Carlo Gambacorti‐Passerini, Michael J. Mauro, Brian Druker, Dong‐Wook Kim, François‐Xavier Mahon, Jörge E. Cortes, Jerry Radich, Andreas Hochhaus, Timothy P. Hughes	84
9	Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation 2012 ·Blood ·Aristeidis Chaidos, Scott D. Patterson, Richard Szydlo, Mohammed S. Chaudhry, Francesco Dazzi, Edward Kanfer, Donald M. McDonald, David Marin, Dragana Milojković, Jiří Pavlů, John Davis, Amin Rahemtulla, Katy Rezvani, John M. Goldman, Irene Roberts, Jane F. Apperley, Anastasios Karadimitris	120
10	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib breakdown → 2010 ·Journal of Clinical Oncology ·David Marín, Alexandra Bazeos, François-Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, (unknown), Kasia Kozlowski, Christos Paliompeis, Victoria Latham, Letizia Foroni, Mathiéu Molimard, Alistair Reid, Katy Rezvani, Hugues de Lavallade, (unknown), John M. Goldman, Jamshid S. Khorashad	674
11	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. 2009 ·Blood ·A. Bazeos, Jamshid S. Khorashad, François‐Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, (unknown), Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John M. Goldman, David Marín	15
12	Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis 2008 ·Journal of Clinical Oncology ·Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad, Dragana Milojković, Alistair Reid, Marco Bua, Richard Szydlo, Eduardo Olavarría, Jaspal Kaeda, John M. Goldman, David Marín	416
13	Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression 2008 ·Journal of Clinical Oncology ·Jamshid S. Khorashad, Hugues de Lavallade, Jane F. Apperley, Dragana Milojković, Alistair Reid, Marco Bua, Richard Szydlo, Eduardo Olavarría, Jaspal Kaeda, John M. Goldman, David Marín	144
14	Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning 2006 ·Blood ·Charles Crawley, Simona Iacobelli, Bo Björkstrand, Jane F. Apperley, Dietger Niederwieser, Gösta Gahrton, (unknown)	121
15	Abstracts 2006 ·British Journal of Haematology ·Jelena Jovanović, J Score, Katherine Waghorn, Alfred Reiter, (unknown), Giuseppe Saglio, Jane F. Apperley, (unknown), Claude Preudhomme, R. Hehlmann, David Grimwade, Nicholas C.P. Cross	3
16	Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. 2004 ·PubMed ·Aloïs Gratwohl, Helen Baldomero, Boris Labar, Jane F. Apperley, Álvaro Urbano-Ispizúa	15
17	Autologous stem cell transplantation in tumour-stage mycosis fungoides: histological and immunophenotypic features as predictors of outcome 2004 ·British Journal of Dermatology ·E. Mary Wain, Eduardo Olavarría, Jane F. Apperley, Guy Orchard, Sean Whittaker, R. Russell‐Jones	3
18	Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group. 2002 ·Blood ·Liang Feng, Mark W. Drummond, Jenny Byrne, P Shepherd, Jane F. Apperley, (unknown), Charles Craddock, Richard E. Clark, Francisco Cervantes, Anne Lennard, Tessa L. Holyoake, Richard Szydlo, J. M. Goldman, Jaspal Kaeda	7
19	Excellent outcome of non-myeloablative stem cell transplant (NMSCT) for good risk myeloma: The EBMT experience 2000 ·Blood ·Marc Lalancette, (unknown), Richard Szydlo, Stephen Mackinnon, Gunnar Juliusson, Marie‐Cécile Michallet, Shimon Slavin, Francesco Frassoni, D Niederwieser, Gösta Gahrton, Jane F. Apperley	12
20	High dose chemotherapy for systemic AL amyloidosis. 1999 ·UCL Discovery (University College London) ·(unknown), Jane F. Apperley, (unknown), Philip N. Hawkins	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact